Our findings resonate with, yet crucially extend, prior work as follows (1): ​NSCLC Evidence:​​ Publications demonstrated that early CRP reduction (within 6–8 weeks) predicted superior OS/PFS in NSCLC patients receiving ICIs (13, 14). Here, CRP is linked to non-small cell lung carcinoma.